Table 1. Baseline Characteristics of Non-small-cell Lung Cancer Patients Initiated on Reduced-Dose Erlotinib as Compared to Patients Initiated on Standard-dose Erlotinib.
| Characteristics | Reduced Dose, n (%) | Full Dose, n (%) | Total, n (%) |
|---|---|---|---|
|
| |||
| N | 31 | 167 | 198 |
|
| |||
| Age at erlotinib start -- yr | |||
| Median | 71 | 60 | 62 |
| Range | 34-95 | 31-90 | 31-95 |
|
| |||
| Sex – no | |||
| Male | 10 (32) | 45 (27) | 55 (28) |
| Female | 21 (68) | 122 (73) | 143 (72) |
|
| |||
| Smoking Status | |||
| Never smoker | 13 (42) | 96 (57) | 109 (55) |
| Ever smoker | 18 (58) | 71 (43) | 89 (45) |
|
| |||
| PS at erlotinib start | |||
| PS 0-1 | 24 (77) | 141 (93) | 165 (91) |
| PS 2-3 | 7 (23) | 10 (7) | 17 (9) |
| Unknown | 0 | 16 | 16 |
|
| |||
| Erlotinib line of therapy | |||
| 1st line | 23 (74) | 119 (71) | 142 (72) |
| 2nd line | 6 (19) | 34 (20) | 40 (20) |
| 3rd line | 2 (6) | 10 (6) | 12 (6) |
| > 3rd line | 0 (0) | 4 (2) | 4 (2) |
|
| |||
| Chemo prior to erlotinib | |||
| No | 23 (74) | 119 (71) | 142 (72) |
| Yes | 8 (26) | 48 (29) | 56 (28) |
|
| |||
| Baseline Brain Metastases | |||
| No | 24 (77) | 114 (68) | 138 (70) |
| Yes | 7 (23) | 53 (32) | 60 (30) |
|
| |||
| EGFR Mutation | |||
| Exon 19 Deletion | 15 (48) | 101 (60) | 116 (59) |
| L858R | 16 (52) | 66 (40) | 82 (41) |
|
| |||
| Date of erlotinib initiation | |||
| Before 12/31/2009 | 10 (32) | 92 (55) | 102 (52) |
| After 12/31/2009 | 21 (68) | 75 (45) | 96 (48) |